Lamivudine Patent Expiration
Lamivudine is Used for treating hepatitis B infection. It was first introduced by Viiv Healthcare Co
Lamivudine Patents
Given below is the list of patents protecting Lamivudine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Epivir |
US6004968 (Pediatric) | Pharmaceutical compositions containing lamivudine |
Sep 20, 2018
(Expired) | Viiv Hlthcare |
| Epivir-hbv |
US6004968 (Pediatric) | Pharmaceutical compositions containing lamivudine |
Sep 20, 2018
(Expired) | Glaxosmithkline |
| Epivir | US6004968 | Pharmaceutical compositions containing lamivudine |
Mar 20, 2018
(Expired) | Viiv Hlthcare |
| Epivir-hbv | US6004968 | Pharmaceutical compositions containing lamivudine |
Mar 20, 2018
(Expired) | Glaxosmithkline |
| Epivir |
US5905082 (Pediatric) | Crystalline oxathiolane derivatives |
Nov 18, 2016
(Expired) | Viiv Hlthcare |
| Epivir-hbv |
US5905082 (Pediatric) | Crystalline oxathiolane derivatives |
Nov 18, 2016
(Expired) | Glaxosmithkline |
| Epivir | US5905082 | Crystalline oxathiolane derivatives |
May 18, 2016
(Expired) | Viiv Hlthcare |
| Epivir | US5905082 | Crystalline oxathiolane derivatives |
May 18, 2016
(Expired) | Viiv Hlthcare |
| Epivir-hbv | US5905082 | Crystalline oxathiolane derivatives |
May 18, 2016
(Expired) | Glaxosmithkline |
| Epivir-hbv |
USRE39155 (Pediatric) | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jan 02, 2014
(Expired) | Glaxosmithkline |
| Epivir-hbv | USRE39155 | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jul 02, 2013
(Expired) | Glaxosmithkline |
Lamivudine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lamivudine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment | Johns Hopkins University | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Reducing Vertical Transmission of Hepatitis B in Africa | University of Alabama at Birmingham | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Lamivudine for Solid Tumors | Thomas Marron | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation | Icahn School of Medicine at Mount Sinai | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine | Fundacion SEIMC-GESIDA | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| STARLITE for Unresectable High-Grade Gliomas | University of Miami | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1 |
| Lamivudine as a Novel Clinical Effort for Rett Syndrome | Maria Denise Fernandes Carvalho de Andrade | NA |
ENROLLING BY INVITATION
(Jun 1, 2026)
| PHASE2 |